Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced positive preliminary results from a Phase I/II clinical study assessing the tolerability, safety, efficacy, and pharmacokinetics of ZG006 in patients with advanced small-cell lung cancer (SCLC) or neuroendocrine carcinoma. The study, which included a dosage escalation and multi-cohort expansion, demonstrated that ZG006 exhibited good tolerability, safety, and excellent anti-tumor efficacy.
In the Phase I dose escalation and expansion study, patients with advanced SCLC who received ZG006 at a dosage of 10mg or more showed significant therapeutic outcomes. As of August 8, 2024, the objective response rate (ORR) was 66.7%, and the disease control rate (DCR) was 88.9%.
ZG006 is a trispecific antibody that targets CD3, DLL3, and DLL3, designed to bridge tumor cells and T cells, thereby stimulating T cells to specifically kill tumor cells. Preclinical studies have indicated that the drug has a significant tumor inhibition effect in mouse tumor models and has shown a favorable safety profile in non-human primates, with minimal toxic side effects. – Flcube.com
